Duvelisib, an oral dual PI3K‐δ,γ inhibitor, efficacy and safety in patients with relapsed or refractory (RR) peripheral T‐cell lymphoma: rationale for the phase 2 PRIMO trial | Zendy

Horwitz S.M. | Zendy; Foss F.M. | Zendy; Porcu P. | Zendy; Moskowitz A. | Zendy; MehtaShah N. | Zendy; Jacobsen E. | Zendy; Khodadoust M.S. | Zendy; Kim Y.H. | Zendy; Weinstock D. | Zendy; Lustgarten S. | Zendy; Baglio M. | Zendy; Youssoufian H. | Zendy; Brammer J. | Zendy

Premium

Duvelisib, an oral dual PI3K‐δ,γ inhibitor, efficacy and safety in patients with relapsed or refractory (RR) peripheral T‐cell lymphoma: rationale for the phase 2 PRIMO trial

Author(s) -

Horwitz S.M.,

Foss F.M.,

Porcu P.,

Moskowitz A.,

MehtaShah N.,

Jacobsen E.,

Khodadoust M.S.,

Kim Y.H.,

Weinstock D.,

Lustgarten S.,

Baglio M.,

Youssoufian H.,

Brammer J.

Publication year - 2019

Publication title -

hematological oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.918

H-Index - 44

eISSN - 1099-1069

pISSN - 0278-0232

DOI - 10.1002/hon.33_2629

Subject(s) - medicine , lymphoma , romidepsin , regimen , oncology , refractory (planetary science) , phases of clinical research , peripheral t cell lymphoma , follicular lymphoma , gastroenterology , clinical trial , pharmacology , immunology , t cell , immune system , chemistry , physics , histone deacetylase , biochemistry , astrobiology , gene , histone

pts, particularly in those with tumors of AITL histology and high CXCL12 expression and enrollment in the CXCL12+ cohort continues.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research